

Holista Colltech Limited
Annual General Meeting 2026

REBUILDING THROUGH GOVERNANCE, DISCIPLINE AND STRATEGIC EXECUTION

Presented by : Mr.Leong Man Loong,
CEO and Executive Director of Holista Colltech
25 May 2026

Holista's Transformation

- Refreshed Board and stronger governance
- Major legacy legal matters substantially resolved
- Liquidity position stabilised
- Leaner operating structure
- Focus returned to execution and commercialisation



FY2025 Financial Overview

FY 2025 Financial Results	AUD'000
Loss before tax	(909)
Debt recoveries	(842)
ASIC settlement	1,090
ProImmune legal fee	394
FY 2025 Loss excluding One-Off items	(267)

Cost Reduction initiatives	AUD'000
Staff cost reduction	380
Directors' fee reduction	85
Other operating cost reduction	51



Final Major Transition

Headwinds	Improvements
ASIC penalty and legal costs	Cost base materially reduced
ProImmune litigation and settlement	Cash management tightened
Legacy restructuring activities	Governance framework strengthened
Ongoing market confidence challenges	Operations stabilised

Charting Recovery

Major legacy legal issues have largely been addressed.

Efforts made to improve governance and business certainty.

Clear strategic direction moving forward.



Collagen Remains Central to Holista's Strategy

- Higher-value nano-collagen applications
- Nutraceutical opportunities
- Cosmetic applications
- Biomedical and wound-care potential
- IP-led commercial model



SCC Joint Venture

- RM5 million funding support; Lower-capex restart structure;
- Shared operational risk; Faster pathway toward recommissioning
- Access to broader market development support through SCC's channels
- Holista retains ownership of existing and future IP
- Revenue from 8% royalty structure
- Option to increase ownership to 75% at pre-determined price
- Preserves long-term strategic upside



Collie Facility 2.0

- New modular production facility; replaces old facility (expired lease)
- Nano-collagen capability integrated into plant design
- Lower fixed operating structure
- Existing collagen buffer stock available
- Land approvals in progress; set up of approx. 6 months
- Operational by Dec 2026

Regenerex Collaboration

- Strategic collaboration with Regenerex Pharma
- Progression of regulatory and trial activities
- Potential medical and wound-care applications
- Commercialisation pathway remains milestone-driven
- Placed order USD52k



Focus Areas : FY2026 & Beyond

- Progress collagen recommissioning
- Execute SCC JV roadmap
- Advance strategic partnerships
- Strengthen recurring revenue streams
- Settle remaining legal issues – ProImmune and legal costs of ASIC matter
- Continue governance and operational discipline



Thank You

HOLISTA